Core Insights - PetVivo Holdings, Inc. will hold a conference call on November 14, 2025, to discuss its fiscal second quarter results for the period ending September 30, 2025 [1][2] - The company focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [4] - PetVivo has a strong product pipeline, including SPRYNG with OsteoCushion technology and PrecisePRP, both currently available for commercial sale [5] Company Overview - PetVivo Holdings, Inc. operates through its subsidiary PetVivo Animal Health, Inc., specializing in biomedical devices for companion animals [4] - The company aims to bring veterinary medical devices to market faster than more regulated pharmaceuticals, enhancing revenue timelines [4] - PetVivo holds a portfolio of twelve patents and six trade secrets protecting its biomaterials and products [5] Upcoming Events - The conference call will include a presentation by management followed by a Q&A session [2] - Dial-in information for the conference call includes a toll-free number and a specific conference ID and passcode [2] - A replay of the conference call will be available on the company's website [3]

MINNEAPOLIS, MN, US, Oct. 28, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID PETVW), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., both emerging biomedical device companies focused on the commercialization of innovative medical therapeutics for companion animals and animal athletes is pleased to announce that Josh Ruben has joined the Company’s Board of Directors. “We are honored to welcome Josh Ruben to our Board of Directors,” said John Lai, Chief Execut ...

Core Insights - Medtronic plc (NYSE:MDT) is recognized as the world's largest manufacturer of biomedical devices and implantable technologies, operating through four primary divisions: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes [2]. Group 1: Price Target and Market Outlook - Stifel raised its price target on Medtronic from $90.00 to $105.00 while maintaining a Hold rating, following a visit to the company's HUGO robotic facility [3]. - The company is reportedly "confidently ready" to introduce its HUGO robotic system in the US, pending expected FDA approval by the end of fiscal 2026 [3]. - Medtronic's strong financial position enhances its prospects for expansion [3]. Group 2: HUGO Robotic System Development - Investors were provided with a detailed look at the HUGO system's development, including live demonstrations of Medtronic's digital ecosystem technologies [4]. - The company plans to adopt "a deliberate and thoughtful approach" for the introduction of the HUGO system to the US market after receiving FDA approval [4]. Group 3: Dividend Appeal - Medtronic's dividend adds to its investment appeal, as the company is close to achieving Dividend King status with 48 consecutive years of dividend increases [5].

Core Insights - PetVivo Holdings, Inc. has entered into note conversion agreements with four existing shareholders to convert $2,018,155 of outstanding promissory notes into 3,669,806 shares of common stock, effectively eliminating over $2 million of debt from its balance sheet [1][4] Group 1: Financial Developments - The total outstanding debt consisted of a principal amount of $1,850,000 and accrued interest of $168,155 [1] - The conversion prices of the notes ranged from $0.50 to $0.75 per share [1] - The successful completion of the note conversion strengthens the company's financial position and allows for more resources to be directed towards product commercialization [4] Group 2: Product Information - PetVivo's signature products include SPRYNG with OsteoCushion Technology, an injectable veterinary medical device that aids in managing joint pain and restoring joint mechanics [2][7] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product designed for intra-articular administration in dogs and horses, providing a consistent dose of 4 billion platelets per vial [3][7] Group 3: Company Overview - PetVivo Holdings, Inc. focuses on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals [6] - The company has a robust pipeline of products protected by twelve patents and six trade secrets [7]

Core Viewpoint - PetVivo Holdings, Inc. is set to present at the Life Sciences Virtual Investor Forum on September 18, 2025, highlighting its innovative medical devices and therapeutics for animals [1][4]. Company Overview - PetVivo Holdings, Inc. is an emerging biomedical device company focused on the commercialization of medical devices and therapeutics for horses and companion animals [5]. - The company aims to leverage human therapies for animal treatment in a capital and time-efficient manner, with a strategy that allows for accelerated revenue timelines compared to pharmaceuticals [5]. Product Information - PetVivo has a robust pipeline of products, including SPRYNG™ with OsteoCushion™ technology for managing joint-related afflictions in animals and PrecisePRP, a first-in-class platelet-rich plasma product [6]. - The company holds a portfolio of twelve patents and six trade secrets that protect its biomaterials and production processes [6]. Event Details - The Life Sciences Virtual Investor Forum will take place on September 18, 2025, from 11:00 to 11:30 am ET, allowing real-time interaction between investors and the company [2]. - Archived webcasts will be available for those unable to attend the live event [2].

Core Points - PetVivo Holdings, Inc. will hold a conference call on August 14, 2025, to discuss its fiscal first quarter results for the period ending June 30, 2025 [1][2] - The company focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [4] - PetVivo has a strong product pipeline, including SPRYNG with OsteoCushion technology and PrecisePRP, both currently available for commercial sale [5] Company Overview - PetVivo Holdings, Inc. operates through its subsidiary, PetVivo Animal Health, Inc., and is dedicated to the manufacturing, commercialization, and licensing of biomedical devices for animals [4] - The company holds a portfolio of twelve patents and six trade secrets that protect its biomaterials and products [5] Conference Call Details - The conference call will take place at 5:00 p.m. Eastern time, with a toll-free dial-in number provided for participants [2] - A replay of the conference call will be available on the company's website [3]

Core Insights - PetVivo Holdings, Inc. has successfully upgraded to trade on the OTCQX Best Market, enhancing its visibility and accessibility for investors [1][3][6] - The company specializes in innovative biomedical devices and therapeutics for horses and companion animals, with key products including SPRYNG with OsteoCushion Technology and PrecisePRP [1][4][5] Company Overview - PetVivo Holdings, Inc. focuses on the manufacturing, commercialization, and licensing of medical devices and therapeutics for equine and companion animals, leveraging human therapies for efficient treatment [7][8] - The company has a robust pipeline of products protected by twelve patents and six trade secrets, indicating a strong intellectual property position [8] Product Details - SPRYNG with OsteoCushion Technology is an injectable veterinary medical device that aids in managing joint pain by restoring proper joint mechanics [4] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product designed for veterinarians, providing a consistent dose of 4 billion platelets per vial [5]

Company Overview - PetVivo Holdings Inc. is an emerging biomedical device company based in Edina, Minnesota, focused on licensing and commercialization of innovative medical devices and therapeutics for equine and companion animals [5][6] - The company aims to leverage investments in human bio-materials and medical device industries to efficiently commercialize products for animals [5] - PetVivo has a robust pipeline of products, including twelve patents and six trade secrets protecting its biomaterials and methods [6] Market Position - PetVivo Holdings has upgraded to trade on the OTCQX Best Market from the OTCQB Venture Market, marking a significant milestone for the company [1][3] - Trading on OTCQX enhances the company's visibility within the investment community and provides greater liquidity and accessibility for investors [4] Product Offerings - The company's lead products include SPRYNG with OsteoCushion technology, an intra-articular injection for managing lameness and joint-related afflictions in animals, and PrecisePRP, a first-in-class platelet-rich plasma product for veterinary use [6]